About us


At Medis Medical Imaging we are leading providers of innovative post-processing software for the quantification of cardiovascular images that enable clinicians, technicians and researchers to accurately perform measurements in medical images. Medis’ solutions help improve the quality of diagnosis, treatment planning and patient follow-up. Our medical imaging software solutions help initiate innovations in research and assess the effectiveness of new treatments and devices.

Management Team

Hans Brons (CEO)

Hans joined Medis in 2019 as CEO. He brings over 28 years of business and general management experience in technology-focused companies of both corporate, start-up and scale-up sizes. Prior to Medis he led Nemo Healthcare and was (co-)founder of several technology-focused companies. He held several senior and general management positions at Philips Electronics, including Philips Healthcare.
Hans gets intrigued by disruptive technology and leading the transformation from new technology into marketable products and sustainable competitive advantage.

Johan (Hans) HC Reiber (CSO)

Johan (Hans) HC Reiber is co-founder (1989) and former CEO of Medis. He is also founder of the Division of Image Processing (LKEB), initially at the Thoraxcenter in Rotterdam in 1976 and from 1990 at the Leiden University Medical center (LUMC). He is emeritus professor for cardiovascular imaging both at the LUMC and the Interuniversity Cardiology Institute of the Netherlands (ICIN), and member of the Royal Netherlands Academy of Arts and Sciences (KNAW). Hans’ ambition has always been to bring innovative image-based quantitation applications into the hands of the clinicians and clinical researchers worldwide. After having served 10 years as CEO of Medis, Hans now serves as Chief Scientific Officer responsible for the Applied Research and he is the primary point-of-contact for internal and external clinical research trials.

Johan Vooren (CCO)

Johan joined Medis early 2020 as Chief Commercial Officer. Prior to joining Medis he has held multiple Senior & Executive positions in various Businesses & Markets in Philips Healthcare and brings with him global sales experience across three continents, Europe, Africa and Asia Pacific.
He has experience in building Business-Market combinations and Product Marketing strategies in both Mature and Emerging Markets; a true commercial leader who brings 25 years of experience in B2B specifically in a commercial environment with a clear focus on and passion for the customer.

Kostas Vlassis (CTO)

Kostas joined Medis in early 2020 as Chief Technology Officer. Previously he held multiple senior technology leadership positions in various sectors like market research, online marketplaces, sustainable technologies and digital healthcare. With over 20 years of experience in a number of key technologies Kostas has led technology teams that delivered world class products and services worldwide. He brings the ability to scale-up technology teams to be more efficient and productive while maintaining a cutting edge advantage through rapid product iterations. Kostas has a MSc Information Systems from Brunel University in London and an MBA from Cass Business School, City University of London.

Supervisory Board

Dharminder Chahal

Dharminder Chahal is owner and managing director of Exponential B.V. in which capacity he acts as consultant to Van Herk Investments and companies in the Van Herk Investments portfolio. Furthermore he is CEO and co-founder of SkylineDx a company based in Rotterdam, The Netherlands, and developing diagnostic tests in oncology. Mr. Chahal has built an extensive network in the global life science industry and created a strong track record in supporting successful companies in their journeys, a.o. Crucell sold to Johnson and Johnson, deVGen sold to Syngenta and Ablynx sold to Sanofi. Currently the main investments in the portfolio are Galapagos, Zealand Pharma (Denmark) and BioInvent (Sweden). As a board member or advisor he has been and still is active for several European companies and funds in the field of life sciences. 

In addition to his board membership at Medis, Mr. Chahal is Chairman of the Board of DCPrime, Sensara and Anemones Hospitality and Hotels (India), Board member of BioInvent (Sweden), VitalneXt and Ceradis and he is Observer of the Board at Bio2 Technologies (US), Miach Orthopaedics (US) and VBHC (India). 

Mr. Chahal previously held various positions in investment banking and asset management, including Kempen & Co and Robeco. Mr. Chahal obtained a master degree in Business Economics (Erasmus University Rotterdam) and a master degree cum laude in Aerospace Engineering (TU Delft). 

Carl J.G. Evertsz

Before joining Medis’ supervisory board in 2018, Carl Evertsz consulted Medis in the areas of business and corporate development and corporate finance. Carl has extensive experience founding, leading, and growing innovative medical imaging companies. He actively led international business, corporate and R&D developments, including M&A and technology acquisitions. Amongst others, he was CEO of MeVis Medical Solutions AG, which he led through a successful IPO in 2007, and CEO of MeVis BreastCare, a joint-venture with Siemens founded in 2001. As business angel he served 4 years at SCiLS GmbH as chairman of the advisory board and since 2014 at ScreenPoint Medical B.V. as a non-executive member of the board of directors.

Pieter de Wit

In various international roles, Pieter fosters the development of small and medium-sized businesses and scale-ups. Currently, Pieter is CFO at DPD Belgium and Luxemburg, which is doubling its revenues in three years and investing more than 60m€ in its infrastructure.

At TNT, Pieter has also been responsible for the venture capital activities, holding various board roles in Europe and the US. Other past management roles include CEO of TNT Innight as well as director planning and control of TNT Group.

As a consultant, Pieter has extensive experience in corporate strategy and M&A, among others at McKinsey & Co and Kempen &Co. He lectures on financial topics, e.g., in corporate valuation at the Rotterdam School of Management.

Our Story


Medis was created in 1989 as a spin-off of the Leiden University Medical Centre (LUMC Netherlands). Our founder and current CSO, Hans Reiber, built the  company focusing on X-ray and image analysis of the heart and with the mission to make these tools available to all medical researchers and specialists.

For over 30 years, Medis has been providing high quality quantitative analysis solutions for cardiovascular imaging to the medical community. Our heritage and core values are based on this strong purpose of contributing to a healthier society by providing the right tools to cardiologists, radiologists, researchers and industry partners.

Medis’ reliable products are internationally appreciated due to our ease of use, and due to the clinical outcome for the patients. Based on the principle “to measure is to know” we support medical professionals with determining the best diagnosis and the subsequent treatment strategies for all patients.

Our product creation and realization process is as simple, as it is unique: starting from a medical need that develops from concept to product. We continue to create, research and innovate towards a clinically relevant product.

In Medis, this continuous innovation leads to new products based on new ideas for the ever-changing cardiovascular imaging environment. And at the same time, we remain relevant in a social and sustainable way. At Medis, quality is  key.

We test and validate in the most optimal way and deliver products of the highest quality, without compromise…that is what we have been doing for the last 30 years.

Medis. The value of quality in care.

Our Purpose

At Medis, we are fortunate to be able to contribute to a mission and business that we are passionate about for more than 30 years. 

Our purpose is to improve patients’ lives by empowering medical professionals with the ultimate cardiovascular imaging software solutions.


Our Vision

To be our customers’ and partners’ first choice in cardiovascular imaging solutions, while being the employer where we feel valued for our contribution to the Medis products at all levels of the organization.